Skip to main content
Clinical Trials/NCT00965900
NCT00965900
Unknown
Phase 4

Randomized Controlled Trial Comparing Propranolol, Endoscopic Banding Ligation, and Combined Treatment to Prevent First Variceal Hemorrhage in Patients With Liver Cirrhosis

Korea University1 site in 1 country288 target enrollmentSeptember 2006

Overview

Phase
Phase 4
Intervention
Endoscopic band ligation
Conditions
Variceal Bleeding
Sponsor
Korea University
Enrollment
288
Locations
1
Primary Endpoint
First esophageal variceal bleeding
Last Updated
8 years ago

Overview

Brief Summary

This study is performed to compare the efficacy and safety of EBL, propranolol, and EBL combined with propranolol in patients with medium or large varices.

Detailed Description

Current guidelines recommend prophylactic treatment with propranolol or endoscopic band ligation (EBL) to prevent variceal bleeding in patients with medium or large varices. However, it is unclear which treatment is more useful in regard to prevention of variceal bleeding as well as safety. In addition, the efficacy and safety of the combination of EBL and propranolol is not still defined. This study is performed to compare the efficacy and safety of EBL, propranolol, and EBL combined with propranolol in patients with medium or large varices.

Registry
clinicaltrials.gov
Start Date
September 2006
End Date
May 2021
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Soon Ho Um

Professor

Korea University

Eligibility Criteria

Inclusion Criteria

  • Liver cirrhosis
  • Age between 18 and 70 years
  • Esophageal varices with high bleeding risk: more than F2 and red color sign
  • No previous history of upper gastrointestinal bleeding
  • No previous history of endoscopic, radiologic, or surgical therapy for varices or ascites
  • Do not take beta-blocker, ACE inhibitor, or nitrate
  • Child-Pugh score \<12

Exclusion Criteria

  • Patients with systolic blood pressure \<100 mmHg or basal heart rate \<60/min
  • Portal vein thrombosis
  • Uncontrolled ascites or hepatic encephalopathy
  • Severe coagulation disorder: prothrombin time \<40% (or INR \>1.7) or platelet count \<30,000/mm3
  • Medium or large sized gastric or duodenal varices
  • Coexisting malignancy
  • Severe cardiovascular disorder, renal failure, peritonitis, sepsis
  • Severe erosive esophagitis, severe esophageal stricture, active gastric or duodenal ulcer
  • Contraindication to beta-blocker
  • Pregnancy

Arms & Interventions

Endoscopic band ligation

Endoscopic band ligation until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment

Intervention: Endoscopic band ligation

Propranolol

start with 20 mg b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)

Intervention: Propranolol

EBL+Propranolol

* EBL until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment * start with 20 mg of propranolol b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)

Intervention: EBL+Propranolol

Outcomes

Primary Outcomes

First esophageal variceal bleeding

Time Frame: 3 years after enrollment

First esophageal variceal bleeding after enrollment

Secondary Outcomes

  • Mortality; Significant esophageal variceal bleeding; Upper gastrointestinal bleeding except esophageal bleeding; Adverse events(3 years after enrollment)

Study Sites (1)

Loading locations...

Similar Trials